Prospective study to assess the association of the treatment outcomes and the quality of life in advanced urothelial carcinoma

Prospective study to assess the association of the treatment outcomes and the quality of life in advanced urothelial carcinoma - Prospective study to assess the association of the treatment outcomes and the quality of life in advanced urothelial carcinoma

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000046249

Enrollment

100

Registered

2021-12-15

Start date

2021-12-15

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Metastatic Urothelial Carcinoma

Interventions

Enfortumab vedotin

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients treated with enfortumab vedotin

Exclusion criteria

Exclusion criteria: cognitive function decline

Design outcomes

Primary

Measure	Time frame
quality of life, cognition	—

Countries

Japan

Contacts

Public Contactkazumasa komura

Osaka Medical and Pharmaceutical University Department of Urology

kazumasa.komura@ompu.ac.jp+81-726-83-1221

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026